Gastric Carcinoma CRISPR Knockout Models for Drug Discovery

According to the World Health Organization (WHO) GLOBOCAN 2022, gastric carcinoma is the fifth most frequently diagnosed cancer worldwide, with over 1.1 million new cases and approximately 770,000 deaths annually, making it the fourth leading cause of cancer mortality. Key risk factors include Helicobacter pylori infection, smoking, high salt intake, and genetic predisposition (e.g., CDH1 mutations in hereditary diffuse gastric cancer). The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database reports a 5-year relative survival rate of 33% for all stages combined, dropping to 6% for distant-stage disease. Early-stage (localized) survival is 72%, highlighting the urgent need for improved early detection and targeted therapies.

Gastric carcinoma is an ideal model for mechanistic studies due to its well-defined molecular subtypes (e.g., The Cancer Genome Atlas (TCGA) classification: EBV-positive, microsatellite unstable, genomically stable, and chromosomally unstable). Public datasets from TCGA, COSMIC, and DepMap provide extensive genomic, transcriptomic, and functional data. Open questions include the role of tumor heterogeneity in therapy resistance, the interplay between immune microenvironment and genetic drivers, and the identification of synthetic lethal vulnerabilities. Gene-edited cell models enable precise dissection of these mechanisms.

Gastric carcinoma arises from a multistep process involving chronic inflammation, genetic alterations, and epigenetic changes. Key pathways include:

1. Helicobacter pylori infection: Induces chronic gastritis, leading to atrophic gastritis, intestinal metaplasia, dysplasia, and carcinoma (Correa cascade).

2. CDH1 loss: In hereditary diffuse gastric cancer, germline mutations in CDH1 (E-cadherin) cause loss of cell adhesion and promote invasion.

3. TP53 mutation: Occurs in ~50% of gastric cancers, disrupting cell cycle arrest and apoptosis.

4. Microsatellite instability (MSI): Defective DNA mismatch repair leads to hypermutation and activation of oncogenic pathways.

Data from TCGA (Nature, 2014) and COSMIC (v99) reveal recurrent alterations in gastric carcinoma:

Key signaling networks driving gastric carcinoma:

• • Wnt/beta-catenin pathway: Nuclear accumulation of beta-catenin due to APC loss or CTNNB1 mutation (5-10%) leads to transcription of MYC and CCND1.
• • MAPK/ERK pathway: KRAS/BRAF mutations (BRAF ~2%) activate MEK/ERK, promoting proliferation.
• • PI3K/AKT/mTOR pathway: PIK3CA mutations or PTEN loss (5-10%) activate survival signaling.
• • TGF-beta pathway: Loss of TGFBR2 (in MSI tumors) or SMAD4 mutations (5%) disrupt growth inhibition.
• • Receptor tyrosine kinases: ERBB2 (HER2) amplification (10-20%) activates downstream signaling; MET amplification (5%) promotes invasion.

Commonly used gastric carcinoma cell lines and their key mutations (from NCBI Gene and COSMIC):

Organoid models derived from patient tumors recapitulate the histological and genetic diversity of gastric cancer, including diffuse and intestinal subtypes. They are valuable for drug sensitivity testing and personalized medicine studies.

Animal models for gastric carcinoma research:

• • Patient-derived xenografts (PDX): Implantation of human tumor fragments into immunodeficient mice, preserving tumor heterogeneity and drug response profiles.
• • Genetically engineered mouse models (GEMM): Examples include:
• • K19-Wnt1/C2mE: Transgenic mice expressing Wnt1 and COX-2 under the keratin 19 promoter, developing gastric tumors.
• • Tff1 knockout mice: Spontaneous gastric adenomas due to loss of trefoil factor 1.
• • CDH1 conditional knockout: Loss of E-cadherin in gastric epithelium leads to diffuse-type carcinoma.
• • Induced models: Chemical carcinogens (e.g., N-methyl-N-nitrosourea) combined with H. pylori infection to mimic human disease progression.

CRISPR/Cas9 technology enables the generation of isogenic cell models with precise genetic modifications, such as knockouts, knock-ins, and point mutations. These models allow researchers to study the functional impact of specific alterations in a controlled genetic background. Examples include:

• • TP53 knockout in AGS cells: Confirms the role of p53 loss in genomic instability and chemoresistance.
• • KRAS G12D knock-in in MKN45 cells: Models oncogenic MAPK signaling and enables testing of KRAS inhibitors.
• • CDH1 knockout in NCI-N87 cells: Recapitulates E-cadherin loss and invasive phenotype.

Commercially available, sequence-verified gene-edited cell lines accelerate research by eliminating the need for in-house editing and validation, ensuring reproducibility and saving time. These models are widely used for target validation, drug screening, and mechanistic studies.

Gene-edited cell lines are essential for functional genomics studies. For example:

• • TP53 knockout in AGS cells demonstrated that p53 loss enhances sensitivity to DNA-damaging agents like cisplatin, but confers resistance to targeted therapies such as MDM2 inhibitors.
• • ARID1A knockout in MKN45 cells revealed that loss of ARID1A increases sensitivity to EZH2 inhibitors, identifying a potential synthetic lethal interaction.
• • CDH1 knockout in NCI-N87 cells showed that E-cadherin loss activates the PI3K/AKT pathway, providing a rationale for combining AKT inhibitors with standard chemotherapy.

Isogenic cell pairs (e.g., wild-type vs. KRAS G12D knock-in) enable high-throughput drug screening to identify compounds that selectively target mutant cells. For example:

• • KRAS G12D isogenic models have been used to screen for inhibitors that block downstream MAPK signaling, leading to the identification of MEK inhibitors as potential therapeutics.
• • Resistance modeling: Chronic exposure of TP53 knockout cells to cisplatin can generate resistant sublines, which can be analyzed to identify mechanisms of resistance (e.g., upregulation of drug efflux pumps or activation of alternative survival pathways).

CRISPR-based synthetic lethality screens in gastric carcinoma cell lines can identify novel biomarkers and therapeutic targets. For example:

• • A genome-wide CRISPR screen in ARID1A-deficient cells identified the DNA repair protein ATR as a synthetic lethal target, suggesting that ATR inhibitors may be effective in ARID1A-mutant gastric cancers.
• • Screens in CDH1 knockout cells revealed that loss of E-cadherin sensitizes cells to inhibitors of the SRC kinase, providing a biomarker for patient stratification.

Key public databases for gastric carcinoma research: